Our Pipeline
Explore
A tetravalent, bispecific dual-antagonist antibody engineered by the fusion of TALTZ® (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF.
An anti-IL-7Rα inhibitor that has the potential to impact diseases driven by IL-7 and TSLP biological pathways.
A fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent (e.g., RAGE) inflammation.